IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Docket No.: 2813-L

LYMAN, Stewart D. and BECKMANN, M. Patricia

Serial No.

-- to be assigned --

Examiner: Unknown

Filing)

December 19, 1997

Group Art Unit: Unknown

For:

MEDIUM CONTAINING FLT3 LIGAND FOR CULTURING HEMATOPOIETIC CELLS

STATEMENT UNDER 37 CFR 1.821(e)

BOX SEQUENCE

The Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

Dear Sir:

Applicants by their undersigned agent hereby state that no computer readable form of the Sequence Listing is necessary for this application because it would be identical to the computer readable form submitted for and with the following grandparent patent application:

Applicants:

Stewart D. Lyman and M. Patricia Beckmann

Serial No.:

08/162,407

Filed:

December 3, 1993

Title:

LIGANDS FOR FLT3/FLT2 RECEPTORS

Applicants hereby request that the previously filed sequence information be used in the instant application.

Date: Dec- 19, 1947

Respectfully submitted,

Stephen L. Malaska Attorney for Applicant Registration No. 32,655

Immunex Corporation Law Department 51 University Street Seattle, WA 98101

Telephone (206) 587-0430

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date listed below, and is addressed to the Commissioner of Patents and Trademarks, BOX SEQUENCE, Washington, D.C. 20231.

xeenler 19,1997

Signed:

Application No.:08/994,468 NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING **NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

DEC 0 7 1999

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X	 This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
X	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other: the topology of the sequence was not reported.
Applicant Must Provide:	
x	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
	An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
x	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
Fo	questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For Patentin software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE